Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial

Huijie Bian; Zhao-Hui Zheng; Ding Wei; Zheng Zhang; Wen-Zhen Kang; Chun-Qiu Hao; Ke Dong; Wen Kang; Jie-Lai Xia; Jin-Lin Miao; Rong-Hua Xie; Bin Wang; Xiu-Xuan Sun; Xiang-Min Yang; Peng Lin; Jie-Jie Geng; Ke Wang; Hong-Yong Cui; Kui Zhang; Xiao-Chun Chen; Hao Tang; Hong Du; Na Yao; Shuang-Shuang Liu; Lin-Na Liu; Zhe Zhang; Zhao-Wei Gao; Gang Nan; Qing-Yi Wang; Jian-Qi Lian; Zhi-Nan Chen; Ping Zhu

Between Feb 3, 2020, and Feb 10, 2020, we screened 39 patients diagnosed with COVID-19 in Tangdu Hospital. The reasons for screen failure are listed in figure 1. 17 patients signed informed consent and were allocated to meplazumab group. 11 hospitalized patients who met the inclusion criteria and with no exclusion criteria signs were collected as concurrent control in the same period. Demographics, comorbidity, epidemiological exposure, prescribed treatment, signs & symptoms, and case severity were generally balanced across two groups as shown in table 1. The median age of patients was 51 years (IQR 49-67) in meplazumab group and was 64 years (IQR 43-67) in control group. Patients in both groups had epidemiological exposure history. Underlying comorbidity, including diabetes, hypertension, cardiovascular disease, and Parkinson disease, were observed in 52.9% and 36.4% patients in meplazumab and control groups, respectively. All patients had received recommended therapy according to the Diagnosis and Treatment for 2019 Novel Coronavirus Diseases, 18 including All rights reserved. No reuse allowed without permission. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.